Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049569 · ClinicalTrials.gov registry record · NA
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 126
- Enrollment target
NCT00049569: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00049569 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049569, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 126 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining more than one chemotherapy drug with imatinib mesylate may kill more cancer cells. Randomized phase II trial to study the effectiveness of combination chemotherapy and imatinib mesylate in treating children who have relapsed acute lymphoblastic leukemia.
Interventions
- DRUG prednisone
- DRUG methotrexate
- DRUG cytarabine
- DRUG vincristine sulfate
- DRUG pegaspargase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2003-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049569
The ClinicalTrials.gov registry entry for NCT00049569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00049569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049569 about?
NCT00049569 is a clinical study titled "Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining more than one chemotherapy drug with imatinib mesylate may kill more...
What is the current status of trial NCT00049569?
This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2003-01.
What interventions are being tested in trial NCT00049569?
The interventions under investigation include: prednisone (DRUG), methotrexate (DRUG), cytarabine (DRUG), vincristine sulfate (DRUG), pegaspargase (DRUG).
Who is sponsoring clinical trial NCT00049569?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.